Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, T-Cell, Peripheral 4Melanoma 3Neoplasms 2Lymphoproliferative Disorders 2Lymphoma 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphatic Diseases 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myeloid, Acute 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 243Paclitaxel 193Cyclophosphamide 158Docetaxel 134Letrozole 113Capecitabine 113Fulvestrant 106Doxorubicin 103Bevacizumab 87Carboplatin 81exemestane 80Anastrozole 79Lapatinib 70Tamoxifen 69Albumin-Bound Paclitaxel 57palbociclib 54pertuzumab 53Taxes 51Gemcitabine 50Radiotherapy 46eribulin 43pembrolizumab 41Everolimus 41Ado-Trastuzumab Emtansine 41Vinorelbine 38130-nm albumin-bound paclitaxel 35ixabepilone 32Epirubicin 28pegfilgrastim 25liposomal doxorubicin 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms × denileukin diftitox × Clear all
NCT00425672 2018-12-05

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

University of Washington

Phase 1/2 Completed
15 enrolled 13 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡